Rubella - Pipeline Review, H1 2016

  • ID: 3746935
  • Report
  • 45 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Biological E. Limited
  • GlaxoSmithKline Plc
  • Prometheon Pharma, LLC
  • Sinovac Biotech Ltd.
  • MORE
Rubella - Pipeline Review, H1 2016

Summary

‘Rubella - Pipeline Review, H1 2016’, provides an overview of the Rubella pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rubella, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rubella and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rubella
- The report reviews pipeline therapeutics for Rubella by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Rubella therapeutics and enlists all their major and minor projects
- The report assesses Rubella therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Rubella

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Rubella
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Rubella pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biological E. Limited
  • GlaxoSmithKline Plc
  • Prometheon Pharma, LLC
  • Sinovac Biotech Ltd.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Rubella Overview

Therapeutics Development

Pipeline Products for Rubella - Overview

Pipeline Products for Rubella - Comparative Analysis

Rubella - Therapeutics under Development by Companies

Rubella - Therapeutics under Investigation by Universities/Institutes

Rubella - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Rubella - Products under Development by Companies

Rubella - Products under Investigation by Universities/Institutes

Rubella - Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co., Ltd

Beijing Tiantan Biological Products Co., Ltd.

Biological E. Limited

China National Pharmaceutical Group Corporation

Daiichi Sankyo Company, Limited

GlaxoSmithKline Plc

Prometheon Pharma, LLC

Sinovac Biotech Ltd.

Zydus Cadila Healthcare Limited

Rubella - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(measles + mumps + rubella + varicella) (tetravalent) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

(measles + mumps + rubella + varicella) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

(measles + mumps + rubella) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

(measles + mumps + rubella) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

(measles + mumps + rubella) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

(measles + rubella + varicella) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

(measles + rubella) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

(measles + rubella) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

measles + mumps + rubella + varicella vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

VN-0102 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Rubella - Recent Pipeline Updates

Rubella - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Rubella, H1 2016

Number of Products under Development for Rubella - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Rubella - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016

Rubella - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2016

Rubella - Pipeline by Biological E. Limited, H1 2016

Rubella - Pipeline by China National Pharmaceutical Group Corporation, H1 2016

Rubella - Pipeline by Daiichi Sankyo Company, Limited, H1 2016

Rubella - Pipeline by GlaxoSmithKline Plc, H1 2016

Rubella - Pipeline by Prometheon Pharma, LLC, H1 2016

Rubella - Pipeline by Sinovac Biotech Ltd., H1 2016

Rubella - Pipeline by Zydus Cadila Healthcare Limited, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Rubella Therapeutics - Recent Pipeline Updates, H1 2016

Rubella - Dormant Projects, H1 2016

List of Figures

Number of Products under Development for Rubella, H1 2016

Number of Products under Development for Rubella - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Beijing Minhai Biotechnology Co., Ltd
Beijing Tiantan Biological Products Co., Ltd.
Biological E. Limited
China National Pharmaceutical Group Corporation
Daiichi Sankyo Company, Limited
GlaxoSmithKline Plc
Prometheon Pharma, LLC
Sinovac Biotech Ltd.
Zydus Cadila Healthcare Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll